Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.28 AUD | +2.40% | +4.49% | -21.71% |
Mar. 06 | Morgan Stanley Adjusts Healius’ Price Target to AU$1 From AU$1.30, Keeps at Underweight | MT |
Mar. 05 | Australia shares inch lower as miners weigh; GDP data in focus | RE |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.71% | 599M | B- | ||
-15.77% | 8.49B | B+ | ||
+58.90% | 4.08B | C+ | ||
-39.78% | 2.42B | B- | ||
-10.16% | 2.42B | - | ||
-3.01% | 2.33B | B- | ||
-2.53% | 2.01B | C- | ||
-19.90% | 1.53B | A- | ||
-38.30% | 1.26B | C+ | ||
+2.19% | 1.07B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HLS Stock
- Ratings Healius Limited